[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,084,712
  • Shares Outstanding, K 61,903
  • Annual Sales, $ 0 K
  • Annual Income, $ -255,840 K
  • EBIT $ -305 M
  • EBITDA $ -311 M
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.83

Options Overview Details

View History
  • Implied Volatility 52.31% (+2.33%)
  • Historical Volatility 40.34%
  • IV Percentile 5%
  • IV Rank 1.49%
  • IV High 236.20% on 06/20/25
  • IV Low 49.53% on 12/10/25
  • Expected Move (DTE 18) 6.59 (8.02%)
  • Put/Call Vol Ratio 107.24
  • Today's Volume 1,840
  • Volume Avg (30-Day) 566
  • Put/Call OI Ratio 1.35
  • Today's Open Interest 11,451
  • Open Int (30-Day) 7,355
  • Expected Range 75.55 to 88.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.82
  • Number of Estimates 5
  • High Estimate $0.31
  • Low Estimate $-1.13
  • Prior Year $-1.13
  • Growth Rate Est. (year over year) +27.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.00 +9.52%
on 05/21/26
88.28 -6.96%
on 05/11/26
+0.11 (+0.13%)
since 04/29/26
3-Month
65.22 +25.94%
on 03/20/26
95.32 -13.82%
on 04/17/26
+12.14 (+17.34%)
since 02/27/26
52-Week
34.34 +139.20%
on 08/08/25
95.32 -13.82%
on 04/17/26
+45.74 (+125.66%)
since 05/28/25

Most Recent Stories

More News
Apogee Therapeutics to Participate in Upcoming June Conferences

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences....

APGE : 82.14 (+5.55%)
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt  Combined with company's current...

APGE : 82.14 (+5.55%)
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026...

APGE : 82.14 (+5.55%)
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 82.14 (+5.55%)
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and...

APGE : 82.14 (+5.55%)
Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Barchart Research What to Expect from APGE Earnings APGE Generated May 8, 2026 Current Price $83.03 EPS Estimate $$-1.12 Consensus Rating Strong Buy Average Move 4.29% Apogee Therapeutics Reports Monday...

APGE : 82.14 (+5.55%)
Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Barchart Research What to Expect from APGE Earnings APGE Generated May 8, 2026 Current Price $83.03 EPS Estimate $$-1.12 Consensus Rating Strong Buy Average Move 4.29% Apogee Therapeutics Reports Monday...

APGE : 82.14 (+5.55%)
Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Barchart Research What to Expect from APGE Earnings APGE Generated May 8, 2026 Current Price $83.03 EPS Estimate $$-1.12 Consensus Rating Strong Buy Average Move 4.29% Apogee Therapeutics Reports Monday...

APGE : 82.14 (+5.55%)
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 82.14 (+5.55%)
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 82.14 (+5.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Apogee Therapeutics LLC is a biotechnology company advancing novel, potentially therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee Therapeutics LLC is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 89.58
2nd Resistance Point 86.03
1st Resistance Point 84.09
Last Price 82.14
1st Support Level 78.60
2nd Support Level 75.05
3rd Support Level 73.11

See More

52-Week High 95.32
Last Price 82.14
Fibonacci 61.8% 72.02
Fibonacci 50% 64.83
Fibonacci 38.2% 57.63
52-Week Low 34.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.